We are investigating the Board of Directors of Pacific Biosciences of California, Inc. (“PACB” or the “Company”) (NasdaqGS: PACB) for possible breaches of fiduciary duty related to the sale of the company to Illumnia, Inc. Under the terms of the proposed transaction, PACB shareholders are only anticipated to receive $8.00 in cash for each share of PACB common stock owned.